Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use

Completed · Phase 3

Conditions studied: Contraception

In brief

This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.

Key facts

Study ID

NCT04112095

Run by

HRA Pharma

People needed

962

Starts

2019-09-06

Expected to finish

2021-08-05

Last updated by the study team

2022-05-20

Who can join

Age: 11 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women who are willing to purchase (in the pharmacies) or be provided (in the clinics, for women younger than 18 years old) oral contraception for their own use for the purposes of the study

You may not qualify if…

• Cannot read, speak and understand English
• Cannot see well enough to read information on the label

Where it is running

• HRA Pharma Investigational site 1012 — Birmingham, Alabama, United States
• HRA Pharma Investigational Site 1008 — Homewood, Alabama, United States
• HRA Pharma Investigational Site 1038 — Mesa, Arizona, United States
• HRA Pharma Investigational Site 1032 — Phoenix, Arizona, United States
• HRA Pharma Investigational Site 1027 — Cerritos, California, United States
• HRA Pharma Investigational Site 1039 — Downey, California, United States
• HRA Pharma investigational site 1035 — Long Beach, California, United States
• HRA Pharma Investigational Site 1017 — Long Beach, California, United States
• HRA Pharma Investigational Site 1034 — Los Angeles, California, United States
• HRA Pharma Investigational Site 1029 — Los Angeles, California, United States
• HRA Pharma Investigational Site 1028 — Los Angeles, California, United States
• HRA Pharma Investigational Site 1033 — Aurora, Colorado, United States
• HRA Pharma Investigational Site 1023 — Dalton, Georgia, United States
• HRA Pharma Investigational Site 1018 — Griffin, Georgia, United States
• HRA Pharma Investigational Site 1014 — Rosedale, Maryland, United States
• HRA Pharma Investigational Site 1019 — Framingham, Massachusetts, United States
• HRA Pharma Investigational Site 1011 — Andover, Minnesota, United States
• HRA Pharma Investigational Site 1006 — Elk River, Minnesota, United States
• HRA Pharma Investigational Site 1003 — Saint Francis, Minnesota, United States
• HRA Pharma Investigational Site 1020 — Saint Louis Park, Minnesota, United States
• HRA Pharma Investigational Site 1009 — Albuquerque, New Mexico, United States
• HRA Pharma Investigational Site 1007 — Albuquerque, New Mexico, United States
• HRA Pharma Investigational Site 1030 — Bronxville, New York, United States
• HRA Pharma Investigational Site 1013 — New York, New York, United States
• HRA Pharma Investigational Site 1037 — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.